Capillary Leak Syndrome
Advise patients of the risk of capillary leak syndrome (CLS), and to contact their health care professional for signs and symptoms associated with CLS including new or worsening edema, weight gain, shortness of breath, and/or hypotension after infusion. Advise patients to weigh themselves daily [see Warnings and Precautions (5.1)].
Hypersensitivity
Advise patients of the risk of hypersensitivity reactions, and to contact their healthcare professional for signs and symptoms associated with hypersensitivity reactions including rash, flushing, wheezing and swelling of the face [see Warnings and Precautions (5.2)].
Hepatotoxicity
Advise patients to report symptoms that may indicate elevated liver enzymes including fatigue, anorexia and/or right upper abdominal discomfort [see Warnings and Precautions (5.3)].
Contraception
Advise females to avoid pregnancy and to use acceptable contraceptive methods during ELZONRIS treatment and for 1 week after the last dose of ELZONRIS [see Use in Specific Populations (8.3)].
Lactation
Advise women not to breastfeed [see Use in Specific Populations (8.2)].
Manufactured by:
Stemline Therapeutics, Inc.
New York, NY 10022
US License No. 2088
Stemline®
A Menarini Group Company